Subscribe to be notified for updates: RSS Feed

Board of Directors
Jose Barella Chairman of the Board

Jose Barella

Mr. Barella was appointed as Non-Executive Chairman on April 11, 2016. Mr. Barella has significant global experience across the Animal Health, Human Health, Crop Protection and Chemical Industries, having held a variety of senior management and executive positions throughout his career. In February 2015 he was appointed Chairman of Netafim, the world leader in irrigation, based in Tel-Aviv. Prior to that, Mr. Barella served on the Advisory Board of mABxience, a biotech company in Spain, focused on the development, manufacturing and commercialisation of biosimilars for human health. From 2001 to 2013 Jose held several roles at Merial, including leading the Companion Animals Division, serving as the Chief Operating Officer with responsibility over Companion and Production Animals, and finally being appointed CEO of Merial and Senior VP Animal Health and CEO of Merial when the company became a division of Sanofi. Mr. Barella’s experience also includes leadership roles with Cosipa, Alcoa, and Rhone Poulenc’s Brazilian subsidiary, Rhodia Pharma.

Barry Riley_cropped for web

Barrington Marshall Riley

Mr Riley was appointed on May 25, 2007. After qualifying as a Chartered Accountant, he joined the Bowater Organization, where he had responsibility for the finance function at several operations. From there he moved to FMC Corporation, the U.S. conglomerate where he had finance and general management responsibilities for a specialty chemical operation, and also oversaw the head office finance function for all UK operations. He joined Proteus International Plc in 1995 as Finance Director and was closely involved in the merger with Therapeutic Antibodies Inc. in 1999, which became Protherics Plc where he was Finance Director until 2007.

James Hills_cropped for web

James Hills

Mr. Hills was appointed on July 09, 2010. He spent the early portion of his career with The Gillette Company and Coca Cola USA where he held senior positions in both sales and brand management. Later, he became a 50% partner and Chief Executive Officer of Weatherly Consumer Products Inc. (Jobe’s), a company which developed, branded and marketed specialty fertilizers in North America and Europe. Following the sale of that business in 1996, he and a partner started Gulfstream Home & Garden, Inc., a company which is specialised in the branding of specialist insecticide products for home and garden use which they sold in 2005, following nearly ten years of rapid growth.

Eric Wintemute_cropped for web

Eric Wintemute

Eric Wintemute was elected to American Vanguard Corporation’s Chairman and Chief Executive Officer posts in mid-1994. Mr. Wintemute had joined the company in January 1994 as Executive Vice President, Chief Operating Officer, and a member of the Board of Directors following American Vanguard’s acquisition of GemChem Inc., a national and international chemical distribution company he co-founded in 1991. From 1977 to 1982, he worked for American Vanguard in a variety of sales, purchasing, and production control capacities. Previously, as a Vice President and Director of R.W. Greeff & Co. from 1982 to 1991, Mr. Wintemute oversaw the national and international distribution of key American Vanguard chemical products. Mr. Wintemute holds a Bachelors of Science in Economics from the University of California, San Diego.


Bruno Jactel, DVM

Dr. Jactel was appointed as Chief Executive Officer (CEO) in January, 2013. He spent 12 years at Merial Limited, the US$2.6 billion revenue generating Animal Health subsidiary of the Sanofi Group, most recently as combined Chief Strategy Officer and Chief Marketing Officer. As Head of commercial operations in Europe, Dr. Jactel developed successful growth strategies in both OTC and professional channels. He was further responsible for global marketing, brand management, enterprise and franchise strategy, in addition to being a co-chair on the R&D steering committee. During this time, Merial built the most successful consumer brand in animal health history with FRONTLINE (Flea and tick product for pets) reaching $1billion in annual revenue in 2009.

Before working at Merial, Dr. Jactel was Deputy Minister for Economic and Commercial Affairs at the French Embassy in Washington D.C. Prior to that, he was Assistant Professor at National Veterinary School of Alfort, Paris. He is also a recent founder and board member of Hypercell Technologies LLC, an early-stage biotech company developing therapeutic solutions to serious infectious animal diseases. Dr. Jactel is a Doctor of Veterinary Medicine and has a Masters in Economic Sciences from the Sorbonne University in Paris.

He is a member of the Board of Advisors of the Raleigh Chamber of Commerce and is a Board member of the Veterinary School in Paris.